Pandorum Technologies Private Limited, a active private limited company, was established on 16 May 2011 in Bengaluru, Karnataka, India. Engaging in healthtech & medical tech solutions within the professional, scientific and technical sector, it holds CIN: U72200KA2011PTC058650. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹4.76 Cr and a paid-up capital of ₹4.67 Cr.
It upholds a compliant status. Employing 27 professional, Its leadership includes Manish Kumar Belmannu (Nominee Director), Arun Chandru Raja (Director), Tuhin Bhowmick (Director). Past directors included Pratik Bose, Saurabh Srivastava, Sonal Asthana. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Egf 4 & 5, Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City Phas, E 1,, Bengaluru, Karnataka, 560100.
Company Details
Email
**********
Telephone
+91-XXXXXXXXXX
Website
**********
Social Media
**********
Apps
**********
Company Details
CIN/LLPIN
U72200KA2011PTC058650
Registration Number
058650
Incorporation Date
16 May 2011
Authorized Capital
₹4.76 Cr
Paid-Up Capital
₹4.67 Cr
ROC Code
Roc Bangalore
Listing Status
Unlisted
Company Status
Active
Key Metrics
Authorised Capital₹ 4.76 Cr
Paid Up Capital₹ 4.67 Cr
Company Age 14 Year, 8 Months
Last Filing with ROC31 Mar 2024
Revenue Growth****301.44%
Profit Growth****19.88%
Ebitda****13.84%
Net Worth 170.79%
Total Assets****160.82%
Pandorum Technologies Private Limited
Company Report
FY 2025-2026
Comprehensive Company Insights
Explore comprehensive insights into Pandorum Technologies Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Pandorum Technologies Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 301.44% increase. The company also saw a substantial improvement in profitability, with a 19.88% increase in profit. The company's net worth Soared by an impressive increase of 170.79%.
What is the Ownership and Shareholding Structure of Pandorum Technologies?
In 2024, Pandorum Technologies had a promoter holding of 84.86% and a public holding of 15.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Shareholding Pattern (FY 2024)
Promoters: 92.83%
Public: 4.10%
Others: 3.07%
Shareholding Pattern over the Year
FY (2024)
FY (2023)
FY (2022)
FY (2021)
FY (2020)
Promoters
92.83
94.62
94.55
94.55
94.55
Public
4.10
3.89
3.95
3.96
3.98
Others
3.07
1.49
1.50
1.49
1.47
Upgrade Required
Full access to Ownership and Shareholding Structure is available only for users with an active Premium plan.
Pandorum Technologies has a workforce of 27 employees as of Dec 13, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Employee Date
Number of Employees
2020
78,000
2021
80,500
2022
83,200
2023
86,000
2024
89,500
2025
92,000
Upgrade Required
Full access to People is available only for users with an active Premium plan.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pandorum Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pandorum Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Latest Updates, News, and FAQs on Pandorum Technologies
Recent Activity within the Organization
Annual General Meeting
The activity Pandorum Technologies Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Balance Sheet
The activity Pandorum Technologies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore. was completed.
Director Appointment
The activity Sudipta Gautam was appointed as a Nominee Director was appointed as a Nominee Director on 18 Dec 2019 & has been associated with this company since 6 years 1 month . was completed.
Director Appointment
The activity Sailesh Tulshan was appointed as a Director was appointed as a Director on 10 Aug 2018 & has been associated with this company since 7 years 5 months . was completed.
Director Appointment
Progress on Manish Kumar Belmannu was appointed as a Nominee Director was appointed as a Nominee Director on 18 Jul 2018 & has been associated with this company since 7 years 6 months . was documented.
Director Appointment
Sonal Asthana was appointed as a Director was appointed as a Director on 14 Nov 2016 & has been associated with this company since 9 years 2 months . was recorded as a recent event.
PRNewswireBengaluru (Karnataka) [India], March 15: Pandorum Technologies, a leading biotechnology company, announced today the successful closure of a pre-Series B funding round, securing USD 11 million (INR 88 crore) in investment. The funding was sourced from Mr. Ashish Kacholia, Everest Finance Investment, Acebright Pharma and Ms. Bandana Kankani's syndicate along with existing investors Mr. Sunil Kant Munjal and the Indian Angel Network.Founded by Arun Chandru & Dr. Tuhin Bhowmick, the startup company focuses on Tissue Engineering and Regenerative Medicine. With the current round of funding, Pandorum aims to progress towards the First-in-Human study of its Flagship product Kuragenx- the 'Liquid Cornea', to treat corneal blindness. The funding will also allow the company to advance its tunable technology platform that has demonstrated regenerative potential beyond cornea, such as, for liver, lung and neuronal tissues."We are thrilled to have the support of the notable investors, including Mr. Ashish Kacholia- as we continue to innovate and develop therapeutics to restore healthy tissue functions, in order to help the patients suffering from unmet clinical needs. Our flagship product Kuragenx combines proprietary biomaterials with regenerative nanotherapy, guiding the formation of a functional corneal tissue to restore vision. This is a First-in-Class approach that can truly blur the line between treatment and cure" said Dr. Tuhin Bhowmick, Co-Founder & CEO of Pandorum Technologies.Mr. Ashish Kacholia said, "This startup is working on cure for corneal blindness. Though the journey to commercialization is long, amazing payoffs possible for all mankind. Indian science and scientific community making amazing strides.""There's a paradigm shift happening in the Indian biotech and lifescience sector with deep-tech companies like Pandorum pushing boundaries and creating global innovations. My best wishes to the team for what they have set out to accomplish," said Ms. Bandana Kankani from Nexxtmile who invested and also advised on this funding round."It is inspiring to see a company originating from India started by two young founders poised to change the landscape of cornea transplant and blindness in the world. We are glad to support the team as they navigate the path towards commercializing their cornea regeneration platform, Kuragenx," said Mr. Ashish Sheth - Partner at Orbit Financial Capital (OFC). OFC acted as buyside advisor to Acebright Pharma.Corneal opacity is one of the major causes of blindness worldwide, with millions waiting for donor tissues against significant odds. Pandorum's Kuragenx promotes scarless regeneration of cornea tissue to restore vision, as demonstrated in extensive pre-clinical studies. In 2023, Kuragenx was awarded the Orphan Drug Designation by the USFDA, for the treatment of Neurotrophic Keratitis, a form of ulcerative corneal blindness that is currently untreatable or extremely difficult to treat. Pandorum is currently engaged in clinical manufacturing process and IND enabling studies of Kuragenx, with the aim towards the first patient dosing in 2025, after obtaining due regulatory approvals."Giving back vision with something made in the lab, without depending on donor corneas, is truly transformative. Kudos to our team at Pandorum. Could not have been possible without the support of our investors, partners and the Government enabled R&D ecosystem. Indeed, it's a multi-billion dollar global opportunity; more so, this will positively impact millions of lives," said Arun Chandru, Co-Founder & Director of the company.Pandorum has its R&D labs in Bangalore, India and in the Bay Area, San Francisco, USA, and works with prominent global partners. The company has received competitive grants from the Department of Biotechnology, Government of India, and has previously raised funds from marquee investors and VCs including Sunil Kant Munjal, Binny Bansal, T K Kurien, Sachin Bansal, 021 Capital, Indian Angel Network (IAN) Fund, Karnataka Venture Fund (KITVEN), Kotak Investment Advisors and 500 Startups.For more information, visit www.pandorum.comLogo: https://mma.prnewswire.com/media/2362884/Pandorum_Logo.jpg(ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire.will not be responsible in any way for the content of the same)Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor.
India's biotech startups making global impact despite challenges. Bugworks beats superbugs with new antibiotics, Pandorum 3D-prints human tissues for medical research. Both win ET Startup Awards. Bugworks CEO humbled, says last antibiotic breakthrough in 1984. Pandorum aims to make personalized organs. Both funded by BIRAC. Biocon's Kiran Mazumdar-Shaw impressed. Tough for biotech to scale up, but grateful for Indian ecosystem..
What is the CIN of Pandorum Technologies Private Limited?
The CIN of Pandorum Technologies Private Limited is U72200KA2011PTC058650.
Where is Pandorum Technologies Private Limited headquartered?
Pandorum Technologies Private Limited is headquartered at Egf 4 & 5, Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City Phas, E 1,, Bengaluru, Karnataka, 560100.
When was Pandorum Technologies Private Limited incorporated?
Pandorum Technologies Private Limited was incorporated on 16 May 2011.
Who are the current directors of Pandorum Technologies Private Limited?
The current directors of Pandorum Technologies Private Limited are
What is the primary industry of Pandorum Technologies Private Limited?
The primary industry of Pandorum Technologies Private Limited is Professional, Scientific And Technical.
Is Pandorum Technologies Private Limited a listed company?
Pandorum Technologies Private Limited is unlisted.
What is the capital structure of Pandorum Technologies Private Limited?
The authorized capital of Pandorum Technologies Private Limited is ₹4.76 Cr, and the paid-up capital is ₹4.67 Cr.
What is the compliance status of Pandorum Technologies Private Limited?
The compliance status of Pandorum Technologies Private Limited is Compliant.
Explore millions of companies — effortlessly
Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets.
From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.
+91-XXXXXXXXXX